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A B S T R A C T   
Background: Ferritin even though widely recognized as a representative of total body iron stores, its prognostic 
utility is linked with COVID-19. This study was aimed at evaluation of the association of ferritin with severity in 
Coronavirus disease 2019 (COVID-19), hospitalized patients and to test the hypothesis that it is an independent 
predictor of mortality. 
Material and methods: This study was conducted at Chemical Pathology, Department of Pathology and Laboratory 
Medicine, Aga Khan University (AKU), Karachi. Medical records of all in-patients including both genders, and all 
age groups with documented COVID-19 from 1st March to 10th August 2020 were reviewed. The subjects were 
divided into two categories severe and non-severe COVID-19; and survivors and non-survivors. The details were 
recorded on a pre-structured performa. Between-group differences were tested using the Mann–Whitney’s U-test. 
The receiver operating characteristic curve was plotted for ferritin with severity and mortality. A binary logistic 
regression was used to identify variables independently associated with mortality. The data was analyzed using 
Statistical Package for the Social Sciences (SPSS). 
Results: A total of 336 in patients were reviewed as declared COVID-19 positive during the study duration, and 
157 were included in the final analysis including 108 males and 49 females. Statistically significant difference in 
ferritin was found in the two categories based on severity and mortality. Binary logistic regression showed 
ferritin to be an independent predictor of all-cause mortality supplemented with an AUC of 0.69 on ROC analysis. 
Conclusions: Serum ferritin concentration is a promising predictor of mortality in COVID-19 cases.   
1. Introduction 
The novel coronavirus disease 2019 (COVID-19) that emerged in 
December 2019 in Wuhan (Hubei, China), has surprisingly occupied the 
entire globe overwhelmingly, with many countries experiencing the 
second wave [1]. Even though the rapidly evolving clinical course and 
presentation continue to amaze the medical fraternity, cases infected 
with this severe acute respiratory syndrome coronavirus 2 (SAR-
S-CoV-2), often present with severe pneumonia and organ targeted in-
juries involving the liver, heart, and kidneys [2]. 
With the surging devastating effects of the pandemic, the focus of 
scientific efforts was on developing optimal therapeutic regimens to 
combat the virus. Meanwhile, there was also a dire need for early risk 
stratification systems and biomarkers to predict disease progression, to 
identify high-risk patients at an early stage of the infection [3–5]. This 
can optimize management goals, and overcome the shortage of medical 
and material resources which was particularly evident amidst this global 
emergency. 
The primary triggering event, associated with severity and mortality 
has been the inflammatory cytokine storm, characterized by abrupt and 
excess release of pro-inflammatory cytokines including inflammatory 
cytokines released by macrophages particularly the interleukins IL-6, IL- 
10, and tumor necrosis factor (TNF-α) [6]. With this pivotal event of the 
pathophysiological mechanism in perspective, biochemical analysis of 
plasma inflammatory markers and positive acute phase reactants 
including ferritin could be useful for predicting the disease progression 
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[7]. Ferritin occurs as a cytosolic protein in most tissues, although a 
mitochondrial form also exists and nuclear localization has been pro-
posed [8]. Even though widely recognized as a representative of total 
body iron stores, its prognostic utility is linked with acute and chronic 
inflammatory processes and is nonspecifically raised in a variety of such 
disorders, including chronic kidney disease, rheumatoid arthritis, and 
autoimmune disorders, etc. [9]. 
In one study from China with twenty COVID-19 cases, it was found 
that individuals with severe diseases often present with increased serum 
ferritin levels, with a statistically significant difference between severe 
and mild categories [10]. Whereas another study conducted using re-
cords from a large multi-hospital New York City health system demon-
strated poor performance of serum ferritin for the prediction of 
mortality [11]. 
Owing to the scarcity of literature on the role of ferritin, and the 
contrasting results demonstrated by various studies on the potential 
association with severity and mortality in context, this study was aimed 
at evaluation of the association of the biomarker with severity in a 
cohort of hospitalized cases with COVID-19 at a tertiary care referral 
center in Karachi, the metropolis hardest hit by the pandemic in 
Pakistan. 
2. Material and Methods 
This retrospective observational study was conducted at the section 
of chemical pathology, department of Pathology and Laboratory Medi-
cine, in collaboration with the section of molecular pathology and 
intensive care unit, department of Internal Medicine, Aga Khan Uni-
versity (AKU), Karachi, Pakistan. The hospital was the first to launch 
treatment facilities for COVID-19 in Pakistan. Being accredited by the 
Joint Commission International (JCI), the hospital serves a population 
from across the country. The hospital houses the leading infectious 
disease consultants of the country alongside dedicated areas for COVID- 
19 screening and treatment with optimal infection control practices. The 
study was approved by the institutional ethical review committee of the 
AKU, Karachi (ERC#2020-5168-14099). Our study was registered with 
Chinese Clinical Trial Registry (Registration No: ChiCTR2100042375). 
This work has been reported in line with the STROCSS criteria [12]. 
Medical records of all in-patients including both genders and all age 
groups with SARS-CoV-2 positive on a reverse-transcriptase polymerase 
chain reaction (PCR) test from 1st March to 10th August 2020 were 
reviewed. The PCR specimen was collected on a nasopharyngeal swab 
using Cobas® SARS-CoV-2 Qualitative assay for use on the Cobas® 
6800/8800 Systems (Roche Molecular Systems). 
The demographic details, length of stay in the hospital, and outcome 
(survived or expired) at the time of discharge along with the results of 
ferritin levels were recorded on a pre-structured questionnaire. Of all the 
COVID-19-positive patients, only hospitalized patients aged 18 years 
and older with a ferritin level available over admission were included in 
the analysis. Owing to the limitations of retrospective data analysis, 
ferritin levels obtained within 48 h of admission were acquired. If 
multiple ferritin levels were obtained, then the one closest to admission 
was recorded. Serum ferritin was measured by Chemiluminescence 
immunoassay (CLIA) on the Siemens Advia Centaur immunoassay 
analyzer using the manufacturer’s recommendations. Results are 
expressed as nanogram of ferritin per microliter of serum (ng/mL). For 
internal quality control, 2 levels of manufacturer-provided controls (low 
and high) were run with each batch of analyte while the laboratory is 
accredited by the College of American Pathologists (CAP), ensuring 
optimal external quality assurance. 
For assessing the role of ferritin in mortality prediction, the study 
sample was further divided into two groups i.e. survivors and non- 
survivors. Likewise, two groups were formulated to assess’ severity, 
being defined as having either of the two criteria; requiring intensive 
care admission or assisted respiration based on invasive ventilation or 
non-invasive oxygen support. 
The data was analyzed using Statistical Package for the Social Sci-
ences (SPSS) version 26 (IBM Corp., Armonk, NY). As the data that was 
skewed; median values were reported along with interquartile ranges 
(IQR) for continuous variables. Between-group median differences were 
tested using the Mann–Whitney’s U-test for continuous. P < 0.05 was 
considered statistically significant and P < 0.01 as highly significant. 
The receiver operating characteristic curve (ROC) was plotted to further 
appraise the relationship of ferritin with severity and mortality respec-
tively and the area under the curve (AUC) calculated. The cut-off values 
were determined as the maximum value giving the best balance between 
sensitivity and specificity. Moreover, a binary logistic regression was 
also used to evaluate the association with mortality. 
3. Results 
A total of 336 inpatients were reviewed as declared COVID-19 pos-
itive during the study duration. Ninety-seven cases i.e. 29% were 
excluded in the data collection phase as they opted out from their 
treatment at AKU after a positive COVID-19. The study sample was 
further scrutinized based on the exclusion criteria and a total of 157 
cases were included in the final analysis as shown in Fig. 1. There were a 
total of 86 (55%) cases in the severe category and out of these 28 (33%) 
progressed to mortality. Whereas, 71 (45%) of the non-severe category 
survived. 
The demographic details, length of hospital stay, and serum ferritin 
levels in the severe and non-severe groups and survivor and non- 
survivor groups respectively are depicted in Table 1 and Table 2. Me-
dian ferritin being 828.5(IQR: 428.5–1386.7) and 357.5(IQR: 
198.91098) ng/mL was found to be significantly higher in the severe 
group compared to the non-severe cases group respectively (p value =
0.005) however the association with severity was lost on binary logistic 
regression analysis (p value = 0.082). Whereas, the ferritin levels with a 
median value of 1096.4 ng/mL in the non-survivor group, were found to 
be significantly higher compared to survivors (p-value = 0.02) and was 
found to be an independent predictor of mortality on binary logistic 
regression (p-value = 0.02). Furthermore, older age and increased 
duration of hospital stay were also revealed as variables independently 
associated both with severity and mortality as shown in Tables 1 and 2. 
ROC curve analysis was used to compare the performance of ferritin 
as a predictor of mortality and severity. Ferritin was a slightly better 
predictor of mortality than severity, with an AUC of 0.69 (95% CI: 
0.58–0.79) and 0.66 (95% CI: 0.57–0.74) respectively as illustrated in 
Fig. 2. The optimal cut-off for prediction of mortality was 574.5 ng/mL 
with a sensitivity of 82% at the cost of specificity i.e. 51%. Whereas, for 
the prediction of severity the optimal cut-off identified was 354 ng/mL 
with a sensitivity of 80% at a compromised specificity i.e. 50%. The 
study sample was further categorized into three categories based on 
serum ferritin levels <500, >500, and >1000 ng/mL, and the case dis-
tribution according to severity and mortality was assessed as shown in 
Fig. 3. In the third category of >1000 ng/mL most of the severe cases (n 
= 39, 40%) and the majority of the expired cases (n = 14, 50%) were 
placed. 
4. Discussion 
During the global COVID-19 pandemic, the role of laboratory med-
icine for aid in clinical decision making was mainly focused on prompt 
risk stratification for smart resource allocation in already exhausted as 
well as resource-constrained setups in the case of low middle-income 
countries (LMIC) like Pakistan. Of the various biomarkers evaluated 
by clinicians based on prior experience of viral pathogens majority were 
pro-inflammatory cytokines including IL-6, Procalcitonin, lactate de-
hydrogenase, and C-reactive protein. However, from a laboratorian’s 
perspective, the majority of the small lab set up particularly in LMIC 
does not have most of these biomarkers readily available on their testing 
menu. Whereas, ferritin being a commonly used biomarker in 
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hematologic disorders is widely available and it is relatively inexpen-
sive. The logistics, availability, and financial benefits pose ferritin as a 
potential tool for COVID-19 risk stratification. 
This retrospective analysis of 157 COVID-19 patients admitted to a 
large tertiary referral center, shows that ferritin levels, either obtained at 
presentation or near to admission, are a relatively nonspecific test in 
predicting the evaluated outcomes, namely all-cause mortality, and 
severity. This was shown via several analytic techniques, including ROC 
analysis obtained at optimal cutoff ferritins. There seemed to be some 
moderate predictive power in ferritin being able to discriminate all- 
cause mortality with an AUC of 0.69 and a significant association on 
binary logistic regression. Likewise, Bennouar S et al. have also reported 
an AUC of 0.63 for severity in prediction in a cohort of 330 Algerian 
patients with COVID-19 in the period between the 27th of March and 
22nd of April 2020 [13]. Another study by Jonathan et al., based on a 
retrospective review of 942 adult COVID-19 cases from New York city 
health system database, have also reported almost similar AUC for 
mortality and severity in COVID-19, being 0.63 and 0.68 respectively 
[14]. 
Pastora J et al. in a systematic review on the utility of ferritin in 
COVID-19 has revealed that ferritin concentrations of COVID-19 pa-
tients were generally within the normal range of less than 400 ng/ml in 
patients with the non-severe disease [7]. However, hyperferritinemia 
(ferritin level > 400 μg/L), was observed in patients with a severe 
Fig. 1. Flow diagram of data scrutiny of cases.  
Table 1 
Case details and ferritin in Severe Vs Non-Severe group.   
Severe Cases (n = 86) 
M:F (60:26) 
Non-Severe Cases (n = 71) 
M:F (48:23) 
Mann–Whitney’s U-test (p-value) Binary logistic regression (p-value) 
Age in years (Median IQR) 59.5 (52–70) 54 (39–68) 0.528 0.01 
Length of hospital stay in days (Median IQR) 13 (8–20) 8 (4–12) 0.001 0.002 
Ferritin in ng/mL (Median IQR) 828.5 (428.5–1386.7) 357.5 (198.91098) 0.005 0.082 
P < 0.05 statistically significant and P < 0.01 highly significant. 
Table 2 
Case details and ferritin in Survivor Vs Non-Survivor group.   
Survivor Cases (n = 129) 
M:F (87:42) 
Non-Survivor Cases (n = 28) 
M:F (21:07) 
Mann–Whitney’s U-test (p- 
value) 
Binary logistic regression (p- 
value) 
Age in years (Median IQR) 56 (44.5–66) 65.5 (57.25–76.25) 0.008 0.0001 
Length of hospital stay in days (Median 
IQR) 
9 (6–14) 17 (5–25.75) 0.022 0.012 
Ferritin in ng/mL (Median IQR) 548.9 (248.1–1137.9) 1096.4 (609.75–1614.5) 0.02 0.024 
P < 0.05 statistically significant and P < 0.01 highly significant. 
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disease on admission, precisely between 1.5 and 5.3 times higher in 
patients. In conjunction, our study also exhibited significantly higher 
results in the severe category of cases. Pastora J et al. also evaluated 
studies comparing ferritin levels on admission between COVID-19 pa-
tients between survivors and non-survivors and demonstrated that 
non-survivors showed ferritin levels on admission around 1400 ng/mL, 
which is between 3 and 4 times higher than that observed in survivors. 
Likewise, our findings with a median ferritin of 1096.4 (IQR: 
609.75–1614.5) ng/mL in the all-cause mortality group was coherent 
with similar studies reported from China. 
Our study reported a male predominance with COVID-19 (n = 108, 
69%). Likewise, a retrospective cohort study of 239 hospitalized COVID- 
19 cases from Lombardy, Italy reported 71% of cases being males and 
another report from Wuhan China reported 75% [15,16]. Furthermore, 
the increasing of the patients was an independent predictor of mortality 
as well as a significant association was noted with severity, with the 
median age being 65.5 years and 56 years in the non-survivors and se-
vere category. Results reported by Luo Xiaomin et al. in 298 COVID-19 
cases from China spanning from 30 January to 20 February 2020 s our 
findings, where a high proportion of mortality was noted for the age 
group above 60 years and increasing age was linked with disease 
advancement [17]. In cohesion with our findings, the global literature 
has also demonstrated a high association of mortality with older age and 
mortality in COVID-19 [18,19]. 
The strengths of this study encompass the large patient population 
from a COVID hit metropolis, with an optimal number of patients 
achieving our outcomes of interest and power of the study within a 
relatively short span of time. Our study certain limitations, mostly owing 
to its retrospective nature. Less than half of the patients in our original 
data set had a ferritin value recorded, the missing set if included could 
potentially affect our findings. This study only evaluated ferritins drawn 
within 2 days of presentation, we did not explore the impact of serial 
ferritins over time and how changes in ferritin values could predict 
outcomes. Moreover, pre-COVID-19 ferritin levels were only available 
for one patient who was a known thalassemia case and was excluded. 
Fig. 2. ROC analysis for ferritin against severity and mortality.  
Fig. 3. Distribution of cases (n) with hyperferritinemia in the four study groups.  
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5. Conclusion 
On admission ferritin concentration is a promising predictor of 
mortality, though, it cannot reliably predict severity. However, owing to 
statistically significant results obtained and its widespread availability, 
it is a useful marker of risk scarification in COVID-19 and can be 
considered in combination with clinical details and other laboratory 
tests while designing the patient centered treatment plans. 
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